Vaccinex Inc (VCNX) - News Archive

In the evolving landscape of biopharmaceutical innovation, Vaccinex Inc. has emerged as a key player with its investigational drug pepinemab, a monoclonal antibody showing great potential in treating both head and neck...

In a robust display of innovation, Vaccinex Inc. has recently provided exciting updates on its proprietary ActivMAb platform, a revolutionary technology central to the discovery of therapeutic antibodies. Capitalizing o...

Overview of Pepinemab and its Phase 1b/2 TrialVaccinex Inc. recently presented new findings from the SIGNAL-AD Phase 1b/2 clinical trial of its investigational therapeutic agent, Pepinemab, at the Clinical Trials on Alz...

Vaccinex Inc. Secures $6.2 Million from Warrant Exercises in Strategic Move to Bolster Operations Amid Q3 ChallengesRochester, N.Y. Sept. 18, 2024 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company sp...

Vaccinex Inc., a biotechnology company dedicated to developing therapeutics for neurological diseases, has made significant strides in its clinical and financial arenas. Recently, the company provided updates on the SIG...

Understanding the Promise of Pepinemab: A Novel Approach for Alzheimer s Disease The quest for viable treatments for Alzheimer s disease (AD) remains one of the most formidable challenges in the field of neuroscience. V...

Unveiling Hope: Vaccinex to Present Promising Topline Data for Pepinemab in Alzheimer s Disease at AAIC 2024The relentless quest for a breakthrough in Alzheimer s disease (AD) treatment has led researchers down myriad p...

Patient visits conclude in Alzheimer’s disease clinical trial; Data expected to be presented in July following database lock in June. Vaccinex, Inc. recently announced a significant milestone in the fight against Alzhei...

Vaccinex Announces Agreements for Stock Offering and Reverse Stock SplitRochester, N.Y. - In a recent press release, Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company specializing in innovative treat...

In a breakthrough announcement, Vaccinex Inc., a renowned clinical-stage biotechnology company, has unveiled multiple strategic agreements that grant access to their cutting-edge ActivMAb Antigen Virus Technology. These...

Vaccinex, Inc. Announces Reverse Stock Split: What This Means for InvestorsIn a press release issued on February 15, 2024, Vaccinex, Inc. (NASDAQ: VCNX) announced a 1-for-14 reverse stock split of its issued common stoc...

ROCHESTER, N.Y., Feb. 07, 2024 Vaccinex, Inc. (Nasdaq: VCNX) (Vaccinex or the Company) has made a significant announcement today regarding a private placement transaction. The clinical-stage biotechnology company, known...

In a recent development, Vaccinex Inc, the renowned biotechnology company, has been granted an extension until March 4, 2024, by the Nasdaq stock exchange to regain compliance with its listing rule. The listing rule in...